A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs CPI 613 (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma
- Focus Therapeutic Use
- 08 Jan 2019 According to a Rafael Pharmaceuticals media release, the company has intiated the patient enrollment in this study.
- 04 Jul 2018 New trial record
- 29 Jun 2018 According to a Rafael Pharmaceuticals media release, Dr. Noy from Memorial Sloan-Kettering Cancer Center is the principal investigator for this study.